Alexandra K. Golant, MD

A pediatric case highlights the challenges of managing severe atopic dermatitis in infants, emphasizing the need for effective treatment strategies.

An 18-month-old with severe atopic dermatitis experiences rapid flare-ups, prompting a discussion on treatment options and potential triggers.

Explore effective management strategies for atopic dermatitis in children, focusing on non-steroidal options and addressing parental concerns.

Healthcare professionals discuss effective educational strategies for managing chronic skin conditions, emphasizing proactive treatment and patient understanding.

Healthcare professionals discuss effective educational strategies for managing chronic skin conditions, emphasizing proactive treatment and patient understanding.

Explore the innovative role of PDE4 inhibitors in treating atopic dermatitis, highlighting breakthroughs in topical therapies and their efficacy.

Explore the innovative role of PDE4 inhibitors in treating atopic dermatitis, highlighting breakthroughs in topical applications and their efficacy.

Healthcare professionals discuss the balance of safety and effectiveness in prescribing topical steroids and non-steroidal treatments for pediatric patients.

Explore the evolving landscape of pediatric atopic dermatitis treatment, focusing on innovative therapies and strategies to break the steroid cycle.

Experts explore innovative treatments for pediatric atopic dermatitis, emphasizing non-steroidal options and early intervention for better long-term management.

Alexandra Golant, MD discusses how addressing severe, recalcitrant atopic dermatitis remains the most pressing unmet need, with emerging biologics, oral JAK inhibitors, and combination therapies offering promising new approaches for these challenging cases.

Alexandra Golant, MD discusses how cost considerations, insurance barriers, formulary restrictions, and effective caregiver education about proper application will significantly impact the widespread adoption of ruxolitinib cream in pediatric dermatology practice.

Alexandra Golant, MD discusses how regulatory challenges, ethical considerations in pediatric clinical trials, and limited pharmacokinetic data present significant hurdles for pediatric treatment approvals, while topical ruxolitinib cream's targeted mechanism of action and steroid-sparing benefits make it a meaningful addition for younger children.

Alexandra Golant, MD discusses how the availability of topical ruxolitinib data in children as young as age 2 could potentially shift pediatric atopic dermatitis treatment guidelines by providing a non-steroidal alternative with a favorable safety profile.

Alexandra Golant, MD, discusses how advancements in pediatric atopic dermatitis (AD) treatment, including topical Janus kinase (JAK) inhibitors like ruxolitinib, may reshape guidelines, yet hurdles remain in regulatory approval, safety data, and accessibility. Adoption depends on efficacy, cost, insurance, and caregiver education. Unmet needs persist in long-term disease control and tailored pediatric options.

Eli Lilly recently hosted a panel discussion with Olympic athlete Suni Lee to discuss the importance of finding a dermatologist who understands the burden of AD.

Dr. Alexandra Golant shares invaluable practice pearls for optimizing the management of hand and foot atopic dermatitis with the use of systemic treatments.

Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.

Dr Golant continues with the case of the 38-year old patient with atopic dermatitis and explore effective strategies for navigating treatment selection and planning in this condition, focusing on discussing options with patients and instilling confidence in the chosen approach.

Alexandra Golant, MD, shares how sleep improvement is measured and the difference an effective treatment makes for the patient’s entire family.

Alexandra Golant, MD, explains why she is confident in the latest safety and efficacy data from ruxolitinib trials to treat pediatric patients with atopic dermatitis.

Alexandra Golant, MD, presents the case of a 38-year-old Caucasian male construction worker, diagnosed with moderate AD at age 15, and his treatment history with various interventions and physician referral considerations.

Dr. Golant discusses the role of disease severity in her selection of atopic dermatitis treatments, particularly noting the characterization of hand and foot involved patients as often moderate cases, and highlighting the rapid response observed in these areas when treated.

A dermatology expert reviews the role of barrier function in AD and outlines available treatments, emphasizing the importance of moisturizing and rapid options when appropriate, as well as the efficacy of rapid systemic treatments in patients when appropriate.

Alexandra Golant, MD, delves into the prevalence and profound influence of hand and foot involvement in her patients, shedding light on the significant burden it imposes on their quality of life.

Alexandra K. Golant, MD, and Mona Shahriari, MD, share take-home pearls on the management of plaque psoriasis, highlighting the use of topical treatment to simplify the treatment regimen.

Expert dermatologists discuss plaque psoriasis patient populations that may not be ideal candidates for PDE-4 inhibitor treatment, as well as gaps that remain in the plaque psoriasis treatment landscape.

Experts in dermatology comment on the impact of both roflumilast and tapinarof on the treatment of plaque psoriasis.

Drs Alexandra K. Golant and Mona Shahriari review the efficacy data of roflumilast and tapinarof in the treatment of plaque psoriasis.

Expert dermatologists provide an overview of 2 newer topical treatments in the plaque psoriasis landscape, roflumilast and tapinarof.